Therapeutic patents for the treatment of pre-eclampsia

Bibliography

• DEPARTMENT OF HEALTH: Why mothers die: Report on confidential inquiries into maternal deaths in the United Kingdom 1994–1996. London: Stationary Office (1998).
   Google Scholar
• VAUGHAN JP & ABOUZAHR C: Reproductive health: widening horizons. Int. J. Public Health (2000) 78:569.
   Google Scholar
• NATIONAL INSTITUTES OF HEALTH: Working group report on high blood pressure in pregnancy. NIH publication. (2000) No. 00–3029 July, Bethsada.
   Google Scholar
• CUNNINGHAM FG, TWICKLER D: Cerebral edema complicating eclampsia. Am. J. Obstet. Cynecol (2000) 182:94–100.
   PubMed Web of Science ®Google Scholar
• THOMAS SV: Neurological aspects of eclampsia. Neurol Sri. (1998) 1565:37–43.
   Google Scholar
• SHEEHAN HL, LYNCH JB: Pathology of toxaemia of pregnancy. Churchill, Livingstone, London (1973).
   Google Scholar
• LINDHEIMER MB, KATZ Al: Renal physiology and disease in pregnancy. In: The Kidney: Physiology and Pathophysiology, 2nd edition. Seldin DW & Giebisch G (Eds) Raven Press, New York (1992).
   Google Scholar
• DAVISON JM: Edema in pregnancy. Kidney [nt. Suppl (1997) 59:S90–S96.
   Google Scholar
• PRITCHARD JA, CUNNINGHAM FG, PRITCHARD SA, MASON RA: How often does maternal preeclampsia-eclampsia incite thrombocytopenia in the fetus? Obstet. Cynecol (1987) 69:292–295.
   Google Scholar
• BARRON WM, HECKERLING P, HIBBARD JU, FISHERS: Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet. Cynecol. (1999) 94:364–370.
   Google Scholar
• WEINSTEIN L: Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am. J. Obstet. Cynecol (1982) 142:159–167.
   PubMed Web of Science ®Google Scholar
• MARTIN JN, RINEHART BK, MAY WL,MAGANN EF, TERRONE DA, BLAKE PG: The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am. J. Obstet. Cynecol (1999) 180:1373–1384.
   PubMed Web of Science ®Google Scholar
• ESKENAZI B, FENSTER L, SIDNEY S: A multivariate analysis of risk factors for preeclampsia. JAMA. (1991) 266:237–241.
   PubMed Web of Science ®Google Scholar
• DEKKER GA, DE VRIES JI, DOELITZSCH PM et al.: Underlying disorders associated with severe early-onset preeclampsia. Am. J. Obstet. Cynecol (1995) 173:1042–1048.
   PubMed Web of Science ®Google Scholar
• SIBAI BM, GORDON T, THOM E et al: Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. Am. I. Obstet. Cynecol. (1995) 172:642–648.
   PubMed Web of Science ®Google Scholar
• PAGE NM, KEMP CF, LOWRY PJ: Emerging molecular targets for the treatment of pre-eclampsia. Expert Opin Ther Targets. (2001) 5 (3) :395–413.
   PubMedGoogle Scholar
• WALKER JJ: Pre-eclampsia. Lancet. (2000) 356(9237):1260–1265.
   PubMed Web of Science ®Google Scholar
• •Highlights the current situation of antihypertensive drugs used to treat PE.
   Google Scholar
• LYDAKIS C, LIP GY, BEEVERS M, BEEVERS DG: Atenolol and fetal growth in pregnancies complicated by hypertension. Am. Hypertens. (1999) 12 (6) : 541–547.
   PubMed Web of Science ®Google Scholar
• SIBAI, BM, GROSSMAN RA, GROSSMAN HE: Effects of diuretics on plasma volume in pregnancies with long term hypertension. Am J. Obstet. Cynecol (1984) 150(7):31–835.
   Web of Science ®Google Scholar
• HANSSENS M, KEIRSE MJ, VANKELECOM F, VAN ASSCHE FA: Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet. Cynecol (1991) 78(1):128–135.
   Google Scholar
• SELIGMAN SP, BUYON JP, CLANCY RM, YOUNG BK, ABRAMSON SB: The role of nitric oxide in the pathogenesis of preeclampsia. Am. Obstet. Cynecol (1994) 171 (0944–948.
   PubMed Web of Science ®Google Scholar
• VANHOUTTE PM, RUBANYI GM, MILLER VM, HOUSTON DS: Modulation of vascular smooth muscle contraction by the endothelium. Ann. Rev. Physiol. (1986) 48:307–20.
   PubMed Web of Science ®Google Scholar
• KIMURA S, KASUYA Y, SAWAMURA T et al.: Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. j Cardiovasc. Pharmacol (1989) 13\(Supp1.5):55–557.
   Google Scholar
• SAWAMURA T, KASUYA Y, MATSUSHITA Y et al: Phosphoramidon inhibits the intracellular conversion of big endothelin-1 to endothelin-1 in cultured endothelial cells. Biochem. Biophys. Res. Commun. (1991) 174(2):779–784.
   PubMed Web of Science ®Google Scholar
• WOLFF K, NISELL H, CARLSTROM K et al: Endothelin-1 and big endothelin-1 levels in normal term pregnancy and in preeclampsia. Regul Pept. (1996) 67(3):211H216.
   Google Scholar
• CLARK BA, HALVORSON L, SACHS B, EPSTEIN FH: Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am. Obstet. Cynecol (1992) 166(3) :962–968 .
   PubMed Web of Science ®Google Scholar
• AJNE G: WOLFF K, FYHRQUIST F, CARLSTROM K, NISELL H, HEMSENHMORTBERG A: Endothelin converting enzyme (ECE) activity in normal pregnancy and preeclampsia. Hypertens. Pregnancy (2003) 22(3):215H224.
   Web of Science ®Google Scholar
• OLSON GL, SAADE GR, BUHIMSCHI I, CHWALISZ K, GARFIELD RE: The effect of an endothelin antagonist on blood pressure in a rat model of preeclampsia. Am. J. Obstet. Cynecol. (1999) 181(3):638–641.
   PubMed Web of Science ®Google Scholar
• LIAO QP, BUHIMSCHI IA, SAADE G, CHWALISZ K, GARFIELD RE: Regulation of vascular adaptation during pregnancy and post-partum: effects of nitric oxide inhibition and steroid hormones. Hum. Reprod. (1996) 11(12):2777–2784.
   PubMed Web of Science ®Google Scholar
• AHN K, SISNEROS AM, HERMAN SB et al.: Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem. Biophys. Res. Commun. (1998) 243(1):184–190.
   PubMed Web of Science ®Google Scholar
• PATT WC, CHENG XM, REPINE JT et al: Butenolide endothelin antagonists with improved aqueous solubility. J. Med. Chem. (1999) 42(12):2162–2168.
   PubMed Web of Science ®Google Scholar
• TAYLOR RN, VARMA M, TENG NN, ROBERTS JM: Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol Metab. (1990) 71(6):1675–1677.
   PubMed Web of Science ®Google Scholar
• HALIM A, KANAYAMA N, EL MARADNY E et al.: Eclampsia-like seizures and electroencephalographic changes in pregnant rabbits with endothelin-1 injections. Cynecol Obstet. Invest. (1995) 39(1):1–7.
   Google Scholar
• HALIM A, KANAYAMA N, EL MARADNY E, MAEHARA K, BHUIYAN AB, TERAO T: Correlated plasma elastase and sera cytotoxicity in eclampsia. A possible role of endothelin-1 induced neutrophil activation in preeclampsia-eclampsia. Am. .1 Hypertens. (1996) 9(1):33–38.
   Google Scholar
• AJNE G, NISELL H: WOLFF K, JANSSON T: The role of endogenous endothelin in the regulation of uteroplacental and renal blood flow during pregnancy in conscious rats. Placenta (2003) 8–9:813–818.
   Google Scholar
• TANIGUCHI T, MURAMATSU I: Pharmacological knockout of endothelin ET(A) receptors. Life Sri (2003) 74(2-3):405–409.
   PubMed Web of Science ®Google Scholar
• MADSEN KM, NEERHOF MG, WESSALE JL, THAETE LG: Influence of ET(13) receptor antagonism on pregnancy outcome in rats. .1 Soc. Gynecol Investig. (2001) 8(4):239–244.
   Google Scholar
• CERVAR M, PUERSTNER P, KAINER F,DESOYE G: Endothelin-1 stimulates the proliferation and invasion of first trimester trophoblastic cells in vitro-a possible role in the etiology of pre-eclampsia?' Investig. Med. (1996) 44(8):447–453.
   Web of Science ®Google Scholar
• BROUGHTON PIPKIN F, SYMONDS EM: Factors affecting factor angiotensin II concentrations in the human infant at birth. Clin. Sci. Mol Med. (1977) 52:449–456.
   PubMedGoogle Scholar
• HANSSENS M, KEIRSE MJ, SPITZ B, VAN ASSCHE FA: Angiotensin II levels in hypertensive and normotensive pregnancies. Br. J. Obstet. Gynaecol (1991) 98:155–161.
   PubMedGoogle Scholar
• ITO M, ITAKURA A, OHNO Y et al: Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia. j Chit. Endocrinol Metab. (2002) 87(4):1871–1878.
   PubMed Web of Science ®Google Scholar
• BROWN MA, WANG J, WHITWORTH JA: The renin-angiotensin-aldosterone system in pre-eclampsia. Cl/n. Exp. Hypertens. (1997) 19(5-6):713–726.
   PubMed Web of Science ®Google Scholar
• WALLUKAT G, HOMUTH V, FISCHER T et al:. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin ATI receptor. I Clin. Invest. (1999) 103(7):945–952.
   PubMed Web of Science ®Google Scholar
• HANSSENS M, KEIRSE MJ, VANKELECOM F, VAN ASSCHE FA: Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet. Gynecol (1991) 78(1):128–135.
   PubMed Web of Science ®Google Scholar
• WIMALAWANSA SJ, YALLAMPALLI C: Pre-eclamptic toxemia: potential new therapy based on animal studies. Ceylon Med. J. (1998) 43(3):138–146.
   PubMedGoogle Scholar
• D'ORLEANS-JUSTE P, CLAING A, TELEMAQUE S, WARNER TD, REGOLI D: Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. Eur. Pharmacol (1991) 204:329–334.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO D, MATHISON R, HUGGEL HJ et al: The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur. Pharmacol (1987) 134:321–326.
   PubMed Web of Science ®Google Scholar
• THOMPSON GW, HOOVER DB, ARDELL JL, ARMOUR JA: Canine intrinsic cardiac neurons involved in cardiac regulation possess NK1, NK2 and NK3 receptors. Amer. J. Physiol Regul Integrat. Comp. Physiol (1998) 44:1683–1689.
   Google Scholar
• ROCCON A, MARCHIONNI D, NISATO D: Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig. Br. J. Pharmacol (1996) 118(5):1095–1102.
   PubMed Web of Science ®Google Scholar
• PAGE NM: WOODS RJ, GARDINER SM et al.: Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature. (2000) 405(6788):797–800.
   Google Scholar
• BROWNBILL P, BELL NJ: WOODS RJ, LOWRY PJ, PAGE NM, SIBLEY CP: Neurokinin B is a paracrine vasodilator in the human fetal placental circulation. J. Chit. Endocrinol Metab. (2003) 88 (5) :2164–2170.
   PubMed Web of Science ®Google Scholar
• LALIBERTE C, DIMARZO L, MORRISH DW, KAUFMAN S: Neurokinin B causes concentration-dependent relaxation of isolated human placental resistance vessels. Regul Pept. (2004) 117(2):123–126.
   PubMedGoogle Scholar
• PINTADO CO, PINTO FM, PENNEFATHER JN et al.: A role for tachykinins in female mouse and rat reproductive function. Biol. Reprod. (2003) 69(3):940–946.
   PubMed Web of Science ®Google Scholar
• KAMINSKI K, RECHBERGER T: Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension. Am. Obstet. Gynecol. (1991) 165(3):733–736.
   PubMed Web of Science ®Google Scholar
• ADAIR CD, BUCKALEW V, TAYLOR K et al.: Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digmdn-binding immunoglobulin. Am. J. Ntphrol. (1996) 16(6):529–531.
   PubMed Web of Science ®Google Scholar
• TYMIAK AA, NORMAN JA, BOLGAR M et al.: Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc. Natl. Acad. Sci. USA (1993) 90(17):8189–8193.
   PubMed Web of Science ®Google Scholar
• SOMOGYI J, SZALAY J, PANDICS T, ROSTA K, CSERMELY P, VER A: New steroid hormone family: endogenous cardiac glycosides and their role in physiologic and pathologic conditions. Orv Heal (2004) 145(6):259–266.
   PubMedGoogle Scholar
• LOPATIN DA, AILAMAZIAN EK, DMITRIEVA RI et al.: Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. I Hypertens. (1999) 17(8):1179–1187.
   PubMed Web of Science ®Google Scholar
• FURUHASHI N, TSUJIEI M, KIMURA H, OKAMURA K, YAJIMA A: Antithromboxane drug in the treatment of preeclampsia. Gyriecol Obstet. Invest. (1991) 32(3):164–166.
   PubMed Web of Science ®Google Scholar
• SEKI H, KUROMAKI K, TAKEDA S, KINOSHITA K, SATOH K: Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens. Pregnancy (1999) 18(2):157–164.
   PubMed Web of Science ®Google Scholar
• SULLIVAN MH, AHMED Y, ELDER MG: Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy. Prostaglandins (1993) 46(1):21–26.
   PubMedGoogle Scholar
• ZLATNIK MG, BUHIMSCHI I, CHWALISZ K, LIAO QP, SAADE GR, GARFIELD RE: The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia. Am. J. Obstet. Gynecol (1999) 180(5):1191–1195.
   PubMed Web of Science ®Google Scholar
• FERRAZZANI S, DE SANTIS L, CARDUCCI B et al: Prostaglandin: cervical ripening in hypertensive pregnancies. Acta. Obstet. Gynecol Land. (2003) 82(6):510–515.
   PubMed Web of Science ®Google Scholar
• SHAAMASH AH, ELSNOSY ED, MAKHLOUF AM, ZAKHARI MM, IBRAHIM OA, EL-DIEN HM: Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia. Int. J. Gynaecol Obstet. (2000) 68(3):207–214.
   PubMed Web of Science ®Google Scholar
• BUHIMSCHI IA, SAADE GR, CHWALISZ K, GARFIELD RE: The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum. Reprod. Update (1998) 4(1):25–42.
   PubMed Web of Science ®Google Scholar
• MURAD F: Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv. Pharmacol (1994) 26:19–33.
   PubMedGoogle Scholar
• BENYO Z, GORLACH C, WAHL M: Involvement of thromboxane A2 in the mediation of the contractile effect induced by inhibition of nitric oxide synthesis in isolated rat middle cerebral arteries. J. Cereb. Blood Row Metab. (1998) 18(6):616–618.
   PubMed Web of Science ®Google Scholar
• WANG W DIAMOND SL: Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells? Biochem. Biophys. Res. Commun. (1997) 28;233(3):748–751.
   Google Scholar
• GUDE NM, BOURA AL, KING RG et al Evidence for inhibition by endothelium-derived relaxing factor of thromboxane A2 receptor-mediated vasoconstriction in the fetal vessels of the human perfused placenta. Placenta (1992) 13(6):597–605.
   PubMed Web of Science ®Google Scholar
• YALLAMPALLI C, GARFIELD RE: Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am. J. Obstet. Cynecol (1993) 169(5):1316–1320.
   PubMed Web of Science ®Google Scholar
• •Inhibition of nitric oxide synthesis in rats provides an animal model for the study of PE.
   Google Scholar
• HELMBRECHT GD, FARHAT MY, LOCHBAUM L et al: L-arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am..! Obstet. Cynecol. (1996) 175(4 Pt. 0:800–805.
   Google Scholar
• RICHER C, BOULANGER H, ES -SLAMI S, GIUDICELLI JF: Lack of beneficial effects on the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats. BE J. Pharmacol (1996) 119(8):1642–1648.
   PubMed Web of Science ®Google Scholar
• GONZALEZ C, CRUZ MA, GALLARDO V, MIGUEL P CARRASCO G: Relative potency of nitrovasodilators on human placental vessels from normal and preeclamptic pregnancies. Cynecol Obstet Invest. (1997) 43(4):219–224.
   PubMed Web of Science ®Google Scholar
• LUZI G, CASERTA G, IAMMARINO G, CLERICI G, DI RENZO GC: Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. Ultrasound Obstet. Cynecol (1999) 14(2):101–109.
   PubMed Web of Science ®Google Scholar
• LEES C, LANGFORD E, BROWN AS et al: The effects of Snitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet. Cynecol. (1996) 88(1):14–19.
   Google Scholar
• AHOKAS RA, MERCER BM, SIBAI BM: Enhanced endothelium-derived relaxing factor activity in pregnant, spontaneously hypertensive rats. Am. J. Obstet. Cynecol. (1991) 165:801–807.
   PubMed Web of Science ®Google Scholar
• HOBBS AJ: Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol (1997) 18(12):484–491.
   PubMed Web of Science ®Google Scholar
• SELWOOD DL, BRUMMELL DG, BUDWORTH J et al: Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J. Med. Chem. (2001) 44(1):78–93.
   PubMed Web of Science ®Google Scholar
• HECKER M, SESSA WC, HARRIS HJ, ANGGARD EE, VANE JR: The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci.: USA (1990) 87(20:8612–8616.
   PubMedGoogle Scholar
• ANDERSON TW, NERI LC, SCHREIBER GB, TALBOT FD, ZDROJEWSKI A: Letter: ischemic heart disease, water hardness and myocardial magnesium. Can. Med. Assoc. J. (1975) 113(3):199–203.
   PubMed Web of Science ®Google Scholar
• MOTOYAMA T, SANO H, FUKUZAKI H: Oral magnesium supplementation in patients with essential hypertension. Hypertension (1989) 13(3):227–232.
   PubMed Web of Science ®Google Scholar
• MAKRIDES M, CROWTHER CA: Magnesium supplementation in pregnancy. Cochrane Database Syst. Rev (2001) 4:CD000937.
   Google Scholar
• CONRADT A, WEIDINGER H, ALGAYER H: Reduced frequency of gestoses in 0-mimetic treated risk pregnancies with added magnesium therapy. CeburishilIC Frauenheilkd (1984) 44(2):118–123.
   PubMedGoogle Scholar
• SIBAI BM, VILLAR MA, BRAY E: Magnesium supplementation during pregnancy: a double-blind randomized controlled clinical trial. Am. J. Obstet. Cynecol (1989) 161(1):115–119.
   PubMed Web of Science ®Google Scholar
• MAGPIE TRIAL COLLABORATION GROUP: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. (2002) 359(9320:1877–1890.
   PubMedGoogle Scholar
• MCCARTY MF: Magnesium taurate for the prevention and treatment of pre-eclampsia/eclampsia. Med. Hypotheses (1996) 47(4):269–272.
   PubMed Web of Science ®Google Scholar
• MOODLEY J, RAMPERSADH S, BECKER P, NORMAN RJ, O'DONELL D: Serum calcium ion concentrations in eclampsia. S. Air. Med. J. (1987) 19;72(6):382–385.
   Google Scholar
• LOPEZ-JARAMILLO P: Calcium, nitric oxide, and preeclampsia. Semin. Perinatol (2000) 24(0:33–36.
   PubMedGoogle Scholar
• BUCHER HC, GUYATT GH, COOK RJ et al: Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA. (1996) 10;275(14):1113–1117.
   Google Scholar
• MORRIS CD, JACOBSON SL, ANAND R et al.: Nutrient intake and hypertensive disorders of pregnancy: evidence from a large prospective cohort. Am. J. Obstet. Cynecol (2001) 184(4):643–651.
   PubMed Web of Science ®Google Scholar
• WELLS IC, AGRAWAL DK, ANDERSON RJ: Abnormal magnesium metabolism in etiology of salt-sensitive hypertension and Type 2 diabetes mellitus. Biol. Trace Elem. Res. (2004) 98(2):97–108.
   PubMed Web of Science ®Google Scholar
• SAVELIEVA GM, EFIMOV VS, GRISHIN VL, SHALINA RI, KASHEZHEVA AZ: Blood coagulation changes in pregnant women at risk of developing preeclampsia. Int. J Cynaecol Obstet. (1995) 48(0:3–8.
   PubMedGoogle Scholar
• ROBERTS JM, TAYLOR RN, MUSCI TJ, RODGERS GM, HUBEL CA, MCLAUGHIN MK: Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Cynecol (1989)161:1200–1204.
   PubMed Web of Science ®Google Scholar
• •Landmark paper describing the important role of endothelial cell dysfunction in PE.
   Google Scholar
• BAKER PN, KRASNOW J, ROBERTS JM, YEO KT: Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet. Cynecol. (1995) 86(5):815–821.
   Google Scholar
• •First report of elevated levels of vascular endothelial growth factor in PE.
   Google Scholar
• KUPFERMINC MJ, DANIEL Y, ENGLENDER T et al.: Vascular endothelial growth factor is increased in patients with preeclampsia. Am. J. Reprod. Immunol. (1997) 38(4):302–306.
   PubMed Web of Science ®Google Scholar
• SHARKEY AM, COOPER JC, BALMFORTH JR et al.: Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur I Clio. Invest. (1996) 26(12):1182–1185.
   PubMed Web of Science ®Google Scholar
• LYALL F, GREER IA, BOSWELL F, FLEMING R: Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. BE Obstet. Cynaecol. (1997) 104(2):223–228.
   PubMedGoogle Scholar
• LYALL F, YOUNG A, BOSWELL F, KINGDOM JC, GREER IA.: Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypmda at delivery Placenta (1997) 18(4):269–276.
   Google Scholar
• COOPER JC, SHARKEY AM, CHARNOCK -JONES DS, PALMER CR, SMITH SK: VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br Obstet. Cynaecol. (1996) 103(12):1191–1196.
   PubMedGoogle Scholar
• TABIBZADEH S: Human endometrium: an active site of cytokine production and action. Endocr. Rev (1991) 12(3):272–290.
   PubMed Web of Science ®Google Scholar
• POLLARD JW, BARTOCCI A, ARCECI R, ORLOFSKY A, LADNER MB, STANLEY ER: Apparent role of the macrophage growth factor, CSF-1, in placental development. Nature (1987) 330(6147):484–486.
   PubMed Web of Science ®Google Scholar
• DAITER E, PAMPFER S, YEUNG YG, BARAD D, STANLEY ER, POLLARD JW: Expression of colony-stimulating factor-1 in the human uterus and placenta. I Cl/n. Endocrinol. Metab. (1992) 74(4):850–858.
   PubMed Web of Science ®Google Scholar
• YONG K, SALOOJA N, DONAHUE RE, HEGDE U, LINCH DC: Human macrophage colony-stimulating factor levels are elevated in pregnancy and in immune thrombocytopenia. Blood (1992) 80(10:2897–2902.
   PubMedGoogle Scholar
• KEITH JC JR, PIJNENBORG R, LUYTEN C, SPITZ B, SCHAUB R, VAN ASSCHE FA: Maternal serum levels of macrophage colony-stimulating factor are associated with adverse pregnancy outcome. Eur. I Obstet. Cynecol. Reprod. Biol. (2000) 89(1):19–25.
   PubMed Web of Science ®Google Scholar
• PAGE EW: The relation between hydatid moles, relative ischemia of the gravid uterus, and the placental origin of eclampsia. Am. Obstet. Cynecol. (1939) 37:291–293.
   Google Scholar
• LE BOUTEILLER P PIZZATO N, BARAKONYI A, SOLIER C: HLA-G, pre-eclampsia, immunity and vascular events. Reprod. Immunol. (2003) 59(2):219–234.
   PubMed Web of Science ®Google Scholar
• SURRATT N: Severe preeclampsia: implications for critical-care obstetric nursing. Obstet. Cynecol. Neonatal. Nuts. (1993) 22(6):500–507.
   PubMedGoogle Scholar
• LEE X, KEITH JC JR, STUMM N et al.: Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia. Placenta. (2001) 22(10):808–812.
   PubMed Web of Science ®Google Scholar